OREGON HEALTH & SCIENCE UNIVERSITY - TO CARRY OUT DEVELOPMENT FOR A DRUG CANDIDATE SMALL MOLECULE INHIBITOR AGAINST CHIKUNGUNYA VIRUS, AN ALPHAVIRUS THAT CAUSES DEBILITATING AND SOMETIMES LIFE-THREATENING DISEASE IN HUMANS.

On Dec 9, 2025, Department of Health and Human Services obligated $4,696,352 to OREGON HEALTH & SCIENCE UNIVERSITY for to carry out development for a drug candidate small molecule inhibitor against chikungunya virus, an alphavirus that causes debilitating and sometimes life-threatening disease in humans.. The award is classified under NAICS 541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) and issued as a cost plus fixed fee contract. Competition extent: full and open competition with 10 offers received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in PORTLAND, OR. The contract is scheduled through Jul 31, 2026 — approximately 2 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541715 — related awards are listed below.